Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or... see more

Recent & Breaking News (NDAQ:KROS)

Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 22, 2021

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

GlobeNewswire November 15, 2021

Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 11, 2021

Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

GlobeNewswire November 8, 2021

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

GlobeNewswire November 4, 2021

Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

GlobeNewswire November 4, 2021

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting

GlobeNewswire October 4, 2021

Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

GlobeNewswire September 2, 2021

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

GlobeNewswire August 5, 2021

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

GlobeNewswire August 2, 2021

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

GlobeNewswire June 22, 2021

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

GlobeNewswire June 11, 2021

Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2021

Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders

GlobeNewswire May 25, 2021

Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

GlobeNewswire May 14, 2021

Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association

GlobeNewswire May 12, 2021

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

GlobeNewswire May 6, 2021

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 25, 2021

Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference

GlobeNewswire March 5, 2021

Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference

GlobeNewswire March 2, 2021